Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    Revision: v3.4.3 was added. Revision: v3.4.2 was removed.
    Difference
    0.1%
    Check dated 2026-03-06T18:39:36.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    - Added related topics: Bladder cancer and MedlinePlus Genetics to the page.
    Difference
    0.2%
    Check dated 2026-02-27T19:01:05.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page now lists Revision: v3.4.2 and no longer lists Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-13T12:55:02.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Added Revision: v3.4.1; removed Bladder cancer, related topics MedlinePlus Genetics, and Revision: v3.4.0.
    Difference
    0.2%
    Check dated 2026-02-06T09:10:48.000Z thumbnail image
  6. Check
    44 days ago
    Change Detected
    Summary
    Show Glossary and Hide Glossary options were added. Metadata labels were updated with 'Last Update Submitted that Met QC Criteria' and a new 'Revision: v3.4.0' tag, and capitalization of 'No FEAR Act Data' was standardized.
    Difference
    0.3%
    Check dated 2026-01-22T17:58:00.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    Revision label updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-01-15T10:53:26.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.